They found that SLC1A5 was upregulated in endocrine therapy-resistant breast cancer cells, and inhibition of SLC1A5 suppressed the proliferation of breast cancer cells resistant to aromatase inhibitors (Chen et al., 2015). This evidence concerns the gene CYP19A1 and breast cancer.